---

• Huppertz A, Bollmann J, Behnisch R, Bruckner T, Zorn M, Burhenne J, Haefeli WE, Czock D. Differential effect of a continental breakfast on tacrolimus formulations with different release characteristics. Clin Pharmacol Drug Dev 2021;10:899-907.

• Seiberth S, Terstegen T, Strobach D, Czock D. Accuracy of freely available online GFR calculators using the CKD-EPI equation. Eur J Clin Pharmacol 2020;76:1465-1470.

• Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, Weiss J, Zorn M, Haefeli WE, Czock D. Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor voriconazole in healthy volunteers. Clin Pharmacol Ther 2019;106:1290-1298.

• Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. Br J Clin Pharmacol 2019;85:1528-1537.

• Czock D, Spitaletta M, Keller F. Suboptimal antimicrobial drug exposure in patients with renal impairment. Int J Clin Pharm 2015;37:906-16.

• Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, Eisenbach C. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transpl 2014;20:1106-17.

• Grün B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE, Czock D. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Br J Clin Pharmacol 2013;76:787-96.

• Czock D, Keller F, Seidling HM. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol 2012;74:66-74.

• Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, Machleidt C, Weinreich T, Haefeli WE. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010;54:2596-602.

• Czock D, Keller F, Hameister J, Tiefenbach B, Mitzner S. Levomethadone is poorly removed by the molecular adsorbents recirculating system. J Clin Psychopharmacol 2009;29:622-4.

• Czock D, Rasche FM, Boesler B, Shipkova M, Keller F. Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 2009;43:363-9.
• Djaelani YA, Giese T, Sommerer C, Czock D. Pharmacodynamic monitoring of ciclosporin and tacrolimus: insights from nuclear factor of activated T-cell-regulated gene expression in healthy volunteers. Ther Drug Monit 2023;45:87-94.